Pfizer

Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company's largest products by sales are the Pfizer–BioNTech COVID-19 vaccine ($11 billion in 2023 revenues), apixaban ($6 billion in 2023 revenues), a pneumococcal conjugate vaccine ($6 billion in 2023 revenues), palbociclib ($4 billion in 2023 revenues), and tafamidis ($3 billion in 2023 revenues). In 2023, 46% of the company's revenues came from the United States, 6% came from Japan, and 48% came from other countries.
Pfizer has been a publicly traded company for nearly a century, making its debut on the New York Stock Exchange in 1942 under the ticker symbol PFE. Since then, its stock has seen ups and downs, influenced by new drug launches, regulatory shifts, and changing market demand for its medicines and vaccines. As a key player in the healthcare industry, Pfizer is part of major stock indices like the S&P 100 and S&P 500, with major institutional investors such as Vanguard and State Street holding significant stakes.
Pfizer is one of the top pharmaceutical companies in the United States, with a market capitalization of $150.35 billion as of December 31, 2024. It ranks fifth among U.S. pharma companies. As of 2024, the company holds the 69th position on the ''Fortune'' 500 list. Provided by Wikipedia